Antaki, N <br/><br/>
IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4.  [electronic resource] 

 -  Journal of viral hepatitis  Jan 2013 
 - 59-64 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2893 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2893.2012.01621.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antiviral Agents--administration & dosage<br/>Drug Therapy, Combination<br/>Female<br/>Gene Frequency<br/>Genotype<br/>Hepacivirus--drug effects<br/>Hepatitis C, Chronic--drug therapy<br/>Humans<br/>Interferon-alpha--administration & dosage<br/>Interferons<br/>Interleukins--genetics<br/>Logistic Models<br/>Male<br/>Middle Aged<br/>Polyethylene Glycols--administration & dosage<br/>Polymorphism, Single Nucleotide<br/>RNA, Viral--genetics<br/>Recombinant Proteins--administration & dosage<br/>Ribavirin--administration & dosage<br/>Syria<br/>Treatment Outcome<br/>Viral Load